← Back to Search

CAR T-cell Therapy

E7 TCR-T Cells for HPV-Related Cervical and Throat Cancer

Phase 2
Led By Christian Hinrichs, MD
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up five years
Awards & highlights


This trial will test an immunotherapy treatment for HPV-associated cancers, such as cervical and throat cancer. Participants receive a conditioning regimen, cells, and drug to assess response.

Who is the study for?
This trial is for adults with metastatic or recurrent HPV-16+ cancers, including cervical, throat, penile, vulvar, vaginal, and anal cancers. They must have the HLA-A*02:01 allele and measurable disease by RECIST criteria. Participants need proper organ function and an ECOG status of 0 or 1. They should have tried standard therapy or declined it and agree to use contraception.Check my eligibility
What is being tested?
The trial tests E7 TCR-T cell immunotherapy in patients with HPV-associated cancers that are metastatic or resistant to treatment. It includes a conditioning regimen followed by E7 TCR-T cells infusion and aldesleukin administration to evaluate the clinical response.See study design
What are the potential side effects?
Potential side effects may include immune system reactions leading to inflammation in various organs (immune-related adverse events), symptoms related to cytokine release such as fever and fatigue (cytokine release syndrome), infusion reactions during cell transfusion, as well as general discomforts like nausea.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tumor response
Secondary outcome measures
Adverse Events

Trial Design

1Treatment groups
Experimental Treatment
Group I: E7 TCR-T cellsExperimental Treatment1 Intervention
Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Adenocarcinoma, particularly those similar to E7 TCR-T cells, include immunotherapies such as checkpoint inhibitors and genetically engineered T cells. Checkpoint inhibitors, like pembrolizumab, work by blocking proteins that prevent the immune system from attacking cancer cells, thereby enhancing the body's immune response against the tumor. Genetically engineered T cells, such as CAR-T cells, are modified to specifically target cancer cell antigens, leading to direct tumor cell destruction. These treatments are significant for Adenocarcinoma patients as they offer targeted approaches that can potentially improve outcomes by harnessing the body's own immune system to fight cancer more effectively.

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
435 Previous Clinical Trials
65,003 Total Patients Enrolled
3 Trials studying Adenocarcinoma
295 Patients Enrolled for Adenocarcinoma
Christian HinrichsLead Sponsor
2 Previous Clinical Trials
57 Total Patients Enrolled
1 Trials studying Adenocarcinoma
15 Patients Enrolled for Adenocarcinoma
Christian Hinrichs, MDPrincipal InvestigatorRutgers Cancer Institute of New Jersey

Media Library

E7 TCR-T cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05686226 — Phase 2
Adenocarcinoma Research Study Groups: E7 TCR-T cells
Adenocarcinoma Clinical Trial 2023: E7 TCR-T cells Highlights & Side Effects. Trial Name: NCT05686226 — Phase 2
E7 TCR-T cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05686226 — Phase 2
Adenocarcinoma Patient Testimony for trial: Trial Name: NCT05686226 — Phase 2
~5 spots leftby Jan 2025